The Chronic Inflammatory Demyelinating Polyneuropathy Market dynamics are strongly driven by the high cost and required chronic use of immunoglobulin therapies. Since IVIg and SCIg treatments are expensive and mandatory for managing the disease, favorable reimbursement policies in developed regions like North America and Europe are essential market enablers, ensuring sustained financial viability for manufacturers.

Furthermore, the Chronic Inflammatory Demyelinating Polyneuropathy Market dynamics are influenced by the rising pipeline of innovative therapies, particularly those focusing on Monoclonal Antibodies and complement inhibitors. As existing patent expirations approach, pharmaceutical companies are aggressively seeking to introduce novel, high-value proprietary drugs to secure future market share and offer patients more convenient or effective alternatives to traditional treatments.